Aug. 4 at 12:08 AM
Vertex Pharmaceuticals reported Q2 EPS of
$4.73, narrowly beating analysts’ estimates of
$4.72, while revenue rose to
$3.33 billion, ahead of the
$3.22 billion consensus, driven by continued strong demand for its cystic fibrosis portfolio and contributions from newer products.
The company also reaffirmed confidence in its outlook, forecasting full-year 2026 revenue of
$13.1 billion to
$13.2 billion, slightly above the
$13.05 billion Wall Street consensus. The guidance reflects expectations for continued commercial momentum and expansion of its product portfolio.
Vertex shares have gained 10.8% over the past three months and are roughly flat over the past year. Analyst sentiment has been mixed recently, with seven upward and nine downward EPS revisions over the last 90 days.
$VRTX